GSK plc (GSK)

GSK to Cut Billions in Costs and Close Stevenage R&D Site: GSK Stock in Focus

GSK Wins US FDA Approval for Jideytro: What It Means for the Stock

GSK Stock: FDA Approves Lung Cancer Drug From Nuvalent Acquisition

GSK Validates Nuvalent Strategy

FDA Approves GSK's Jideytro for ROS1 Positive Lung Cancer

GSK Accelerates Cancer Pipeline with $10.6 Billion Nuvalent Acquisition

Jefferies Upgrades GSK to Buy Rating

GSK Stock: Chronic Cough Drug Dropped After Late-Stage Trial Miss

GSK Stock: Acquisition of Nuvalent Completed

GSK Completes $10.6 Billion Nuvalent Acquisition to Boost Lung Cancer Pipeline

GSK Stock: Jemperli Hits Goal in Phase 2 Rectal Cancer Trial

GSK Stock in Focus as Jemperli Wins Registrational Trial in Rectal Cancer

GSK Stock in Focus as Jemperli Moves Toward FDA Filing After Rectal Cancer Win

AstraZeneca Stock in Focus as Sino Biopharm Licensing Deal Adds to China Pipeline

GSK Stock in Focus as Nuvalent Buyout Clears US Antitrust Review

GSK Calls China Drug Trial Results a Milestone: What It Means for the Pipeline

Haleon and GSK Stock in Focus as GSK Completes Its Exit From Haleon

GSK Investors Warm to New CEO's Strategy, but Execution Risk Remains

GSK Ends Alector Dementia Alliance After Both Lead Drugs Fail

GSK Ends $700M Alector Alzheimer's Deal After Two Trial Failures

GSK Board Adds Philips Chief Executive Roy Jakobs as Non-Executive Director

GSK Expands Sino Bio Partnership in $4.5 Billion Inhaler Deal

AstraZeneca and GSK Sign Separate Respiratory Licensing Deals With Sino Biopharm

GSK Acquires Nuvalent for $10.6 Billion in Major Oncology Expansion

GSK Stock Rises Ahead of July 28 Q2 Results, Sales Performance in Focus

Sensodyne Pronamel Intensive Enamel Repair from GSK PLC - targeted relief for sensitive teeth - Ad-hoc-news.de

GSK Secures FDA Approval for Utebzi, Momelotinib Gains Orphan Tag: Boost for Pharma Pipeline

US FDA Approves GSK Antibiotic for Drug-Resistant UTIs: Pharmaceutical Stock in Focus

GSK's Momelotinib Receives Orphan Drug Designation in US and EU, Boosting Pipeline Potential

GSK Boosts Oncology Pipeline with $11 Billion Nuvalent Deal: Pharmaceutical Stock in Focus

GSK Acquires Nuvalent for $10.6 Billion, Boosting Oncology Pipeline